TIS: Tenecteplase in Stroke Trial.

Print
Phase IIb, randomised, multicentre, single blinded (outcomes blind to treatment arm) trial of intravenous tenecteplase (TNK) versus alteplase (tPA) in acute ischaemic stroke patients. Three arms (tenecteplase 0.1 mg/kg, tenecteplase 0.25 mg/kg, alteplase 0.9 mg/kg) with 1:1:1 randomisation. Patients randomised to treatment within 1.2 and CTP based infarct core <1/3 middle cerebral artery territory. The primary hypothesis being tested in this trial is that ischaemic stroke patients treated with TNK will have greater reperfusion (measured at 24 hours) than tPA. Secondary outcomes include early clinical improvement and parenchymal haematoma.

A total of 75 participants shall be recruited.
Last Updated ( Sunday, 17 October 2010 21:34 )